VI
The startup is developing second-generation vaccines against SARS-CoV-2, utilizing advanced recombinant protein technology to enhance immune response. This approach aims to provide healthcare professionals with effective treatment options to improve patient recovery from COVID-19.
Updated 3 months ago
Funding
$750K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is developing second-generation vaccines against SARS-CoV-2, utilizing advanced recombinant protein technology to enhance immune response. This approach aims to provide healthcare professionals with effective treatment options to improve patient recovery from COVID-19.